Payment overview · 2025
General Payments
$2,403.85
89 reported records · 23 companies
Healthcare provider profile · identity verified
Josh Weng, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1043219678
Verified facts
What the public records show
CMS Open Payments records show Josh Weng, M.D. received $2,403.85 in general payments during 2025 across 89 reported records.
Amgen Inc. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess, Ozempic, Paxlovid, Rexulti, Teriparatide, Trelegy Ellipta, Tymlos, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $500.18 | 20.8% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $421.40 | 17.5% | 11 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $283.76 | 11.8% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $173.96 | 7.2% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $164.04 | 6.8% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $113.82 | 4.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.10 | 4.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.50 | 2.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.91 | 2.7% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $63.00 | 2.6% | 2 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $58.13 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.43 | 2.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.27 | 2.0% | 2 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $43.80 | 1.8% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.88 | 1.3% | 1 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $29.32 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.73 | 1.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.28 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.35 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.52 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.21 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.88 | 0.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.38 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,403.85 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $445.24 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $421.40 | 11 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $283.76 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $173.96 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $164.04 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $113.82 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $106.10 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $78.84 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $78.16 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.91 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $63.00 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $58.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 230 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 216 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 105 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TERIPARATIDE teriparatide |
2025 | Teriparatide | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
230 | 53 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
139 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
25 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
55 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 46 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
328 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
105 | 100 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1002 | 266 |
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 215 |
| Azithromycin | Azithromycin | 744 | 384 |
| Amlodipine Besylate | Amlodipine Besylate | 698 | 183 |
| Prednisone | Prednisone | 595 | 332 |
| Metformin Hcl | Metformin Hcl | 590 | 151 |
| Losartan Potassium | Losartan Potassium | 473 | 134 |
| Alendronate Sodium | Alendronate Sodium | 448 | 139 |
| Vascepa | Icosapent Ethyl | 427 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 73 |
| Eliquis | Apixaban | 328 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 314 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 309 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 295 | 103 |
| Omeprazole | Omeprazole | 284 | 88 |
| Finasteride | Finasteride | 258 | 80 |
| Carvedilol | Carvedilol | 256 | 60 |
| Trazodone Hcl | Trazodone Hcl | 256 | 80 |
| Icosapent Ethyl | Icosapent Ethyl | 250 | 79 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 233 | 126 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 231 | 58 |
| Creon | Lipase/Protease/Amylase | 230 | 53 |
| Gabapentin | Gabapentin | 225 | 78 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 223 | 55 |
| Montelukast Sodium | Montelukast Sodium | 220 | 78 |
| Jardiance | Empagliflozin | 216 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 209 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 52 |
| Famotidine | Famotidine | 196 | 63 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 190 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 49 |
| Meloxicam | Meloxicam | 185 | 65 |
| Sertraline Hcl | Sertraline Hcl | 182 | 53 |
| Furosemide | Furosemide | 181 | 58 |
| Potassium Chloride | Potassium Chloride | 178 | 54 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 174 | 95 |
| Alprazolam | Alprazolam | 172 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 49 |
| Valsartan | Valsartan | 162 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 48 |
| Atenolol | Atenolol | 153 | 48 |
| Januvia | Sitagliptin Phosphate | 149 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 143 | 105 |
| Linzess | Linaclotide | 139 | 47 |
| Amoxicillin | Amoxicillin | 135 | 96 |
| Lorazepam | Lorazepam | 130 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 50 |
| Allopurinol | Allopurinol | 123 | 32 |
| Ozempic | Semaglutide | 119 | 20 |
| Tramadol Hcl | Tramadol Hcl | 116 | 19 |
| Cyclosporine | Cyclosporine | 115 | 46 |
| Paxlovid | Nirmatrelvir/Ritonavir | 105 | 100 |
| Bethanechol Chloride | Bethanechol Chloride | 101 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 11 |
| Glipizide | Glipizide | 100 | 28 |
| Simvastatin | Simvastatin | 95 | 29 |
| Entresto | Sacubitril/Valsartan | 94 | 22 |
| Naproxen | Naproxen | 93 | 66 |
| Memantine Hcl | Memantine Hcl | 92 | 14 |
| Restasis | Cyclosporine | 91 | 32 |
| Donepezil Hcl | Donepezil Hcl | 90 | 24 |
| Olanzapine | Olanzapine | 88 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 37 |
| Clonazepam | Clonazepam | 84 | 13 |
| Celecoxib | Celecoxib | 83 | 25 |
| Lisinopril | Lisinopril | 83 | 21 |
| Calcitriol | Calcitriol | 79 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | 19 |
| Nifedipine Er | Nifedipine | 76 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 72 | 49 |
| Farxiga | Dapagliflozin Propanediol | 68 | 19 |
| Ibuprofen | Ibuprofen | 68 | 33 |
| Latanoprost | Latanoprost | 68 | 15 |
| Nitroglycerin | Nitroglycerin | 68 | 45 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Tradjenta | Linagliptin | 61 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 13 |
| Pregabalin | Pregabalin | 59 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | 16 |
| Dutasteride | Dutasteride | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 16 |
| Divalproex Sodium | Divalproex Sodium | 57 | 14 |
| Azelastine Hcl | Azelastine Hcl | 55 | 16 |
| Moxifloxacin | Moxifloxacin Hcl | 55 | 43 |
| Prolia | Denosumab | 55 | 42 |
| Temazepam | Temazepam | 55 | 11 |
| Benazepril Hcl | Benazepril Hcl | 54 | 11 |
| Irbesartan | Irbesartan | 54 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 53 | 19 |
| Myrbetriq | Mirabegron | 53 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | 16 |
| Hydrocortisone | Hydrocortisone | 52 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 52 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 23 |
| Lidocaine | Lidocaine | 51 | 18 |
| Mupirocin | Mupirocin | 51 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 40 |
| Famciclovir | Famciclovir | 50 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Glimepiride | Glimepiride | 49 | 12 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 49 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Tymlos | Abaloparatide | 47 | suppressed |
| Metronidazole | Metronidazole | 46 | 39 |
| Raloxifene Hcl | Raloxifene Hcl | 46 | 16 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 45 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 12 |
| Ketoconazole | Ketoconazole | 44 | 23 |
| Rivastigmine | Rivastigmine | 44 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Folic Acid | Folic Acid | 42 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 42 | 27 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 41 | 34 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Colchicine | Colchicine | 38 | 14 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 25 |
| Cephalexin | Cephalexin | 35 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Ursodiol | Ursodiol | 34 | suppressed |
| Baclofen | Baclofen | 33 | 11 |
| Levofloxacin | Levofloxacin | 33 | 28 |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 30 | suppressed |
| Ssd | Silver Sulfadiazine | 29 | 15 |
| Brilinta | Ticagrelor | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 26 | 13 |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Enulose | Lactulose | 26 | suppressed |
| Estradiol | Estradiol | 26 | 16 |
| Repaglinide | Repaglinide | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 17 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 25 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 25 | 15 |
| Clarithromycin | Clarithromycin | 24 | 21 |
| Lactulose | Lactulose | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Fluocinonide | Fluocinonide | 23 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Forteo | Teriparatide | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Permethrin | Permethrin | 12 | 11 |
| Teriparatide | Teriparatide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,403.85 · 89 records | Amgen Inc. | ABRYSVO, ACCRUFER, BREZTRI, CAPLYTA, COMIRNATY, CREON, EVENITY, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, REZDIFFRA, ROXYBOND, TERIPARATIDE, TRELEGY ELLIPTA, TRYNGOLZA, TYRVAYA, Tymlos, VERQUVO, ZENPEP, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error